You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

A Rational Approach to the Management of Recurrent or Persistent Ovarian Carcinoma

THIGPEN, TATE MD

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e31824b9bc5
Ovarian Cancer
Abstract

Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent.

Author Information

Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi

The author declares that he has nothing to disclose.

Correspondence: Tate Thigpen, MD, Division of Oncology, University of Mississippi Medical Center, Jackson, MS. E-mail: jtthigpen@att.net

© 2012 Lippincott Williams & Wilkins, Inc.